UC, MIT Battle Over Patent to Gene-Editing Tool
By Lisa M. Krieger,
San Jose Mercury News
| 05. 09. 2015
Will the University of California reap the financial rewards of CRISPR's commercial use, likely worth billions of dollars? That's the source of a bitter fight.
In June 2012, UC Berkeley's Jennifer Doudna and Emmanuelle Charpentier, now a professor in Germany, showed how bacteria's natural defense system could be turned into a "gene editing" tool to cut DNA strands.
Seven months later, Feng Zhang of the Massachsuetts Institute of Technology, along with Harvard's George Church, showed that the tool also works in human cells.
UC and Doudna filed for a patent first. But in a shocking turn of events, MIT and Zhang won last month, earning the patent that covers use of CRISPR in every species except bacteria, including humans.
MIT paid extra to expedite Zhang's patent application. MIT and Zhang also assert that the patent belongs to them because Doudna didn't prove it works in human cells, only bacterial cells.
Zhang also submitted photos of lab notebooks showing his lab work was ahead of Doudna's.
UC and Doudna are fighting back, submitting thousands of pages of documentation to support their...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Lizzy Lawrence, Stat News | 10.14.2025
By Carter Sherman, The Guardian | 10.16.2025